RxDoctor Payments Data

Karla Carias Martinez, MD

Nephrology · Albuquerque, NMNPI 1265886386

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $269 of the $344 with a category attached, or 78.2%. It is spread thinly across 10 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for nephrology clinicians in NM, where the typical reported total is $1,114.

$344in general payments, 2019–2025

Across 16 payments — averaging $21.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Enterprises LLC$75
  • GSK$54
  • AstraZeneca$46
  • Vifor Pharma, Inc.$37
  • Bayer$36
  • Novo Nordisk$22
  • plus $73 from 4 others

What the payments were for

  • Food & beverage$26978%
  • Education$7522%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$344 in reported general payments places this provider in the 25th percentile of 68 nephrology providers in New Mexico.

See all nephrology providers in New Mexico

Medicare billing

Part B allowed, 2024
$126,303
Medicare patients
264
Services billed
829

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide12$41,811
Cinacalcet Hcl32$21,030
FarxigaDapagliflozin Propanediol19$11,037
KerendiaFinerenone13$8,080
Potassium Citrate ErPotassium Citrate12$1,203
Carvedilol85$980
Losartan Potassium86$919
Torsemide27$727
Nifedipine ErNifedipine27$466
Lisinopril46$401
Allopurinol45$356
Famotidine37$341
Calcitriol28$337
Tamsulosin Hcl22$323
Furosemide44$321

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$46$11,03719 claims
BayerKerendia$36$8,08013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 68 nephrology providers in New Mexico.

Other nephrology in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →